Pharmacological targeting of Sdc-1, therefore, emerges as a potential therapeutic approach in TNBC and possibly additional subtypes of breast cancer, which does not only affect tumorigenic properties such as cell proliferation, invasive growth, and the cancer stem cell phenotype [14,73,74], but also tumor angiogenesis. The gene discussed is SDC1; the disease is breast carcinoma.